Article Text

Download PDFPDF
High-sensitivity cardiac troponin at 3 hours: is the cat among the pigeons?
  1. Richard Body1,2,
  2. Paul Collinson3,
  3. Steve Goodacre4,
  4. Nicholas L Mills5,
  5. Adam Timmis6
  1. 1Central Manchester University Hospitals Foundation NHS Trust, Manchester Academic Health Science Centre, Manchester, UK
  2. 2Cardiovascular Institute, The University of Manchester, Manchester, UK
  3. 3Department of Clinical Blood Sciences, St. George's Healthcare NHS Trust, London, UK
  4. 4School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
  5. 5University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
  6. 6NIHR Biomedical Research Unit, Bart's Heart Centre, London, UK
  1. Correspondence to Dr Richard Body, Emergency Department, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK; richard.body{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In November 2014, the National Institute for Health and Care Excellence (NICE) issued recommendations for the use of high-sensitivity cardiac troponin (hs-cTn) assays in the UK.1 Two assays were evaluated: the Elecsys hs-cTnT assay (Roche Diagnostics) and the ARCHITECT hs-cTnI assay (Abbott Laboratories). On the basis of both clinical and economic evidence, NICE recommended that hs-cTn assays could be used to ‘rule out’ the diagnosis of non-ST elevation myocardial infarction (NSTEMI) within 4 hours of patients arriving in an Emergency Department (ED). NICE further stated that this would typically involve ‘ruling out’ NSTEMI in patients with hs-cTn concentrations below the 99th percentile upper reference limit when tested both on arrival in the ED and 3 hours later. This recommendation was based on the findings of a commissioned systematic review.2 The systematic review had pooled existing evidence from 18 studies to define more granular ‘optimal’ testing strategies for each hs-cTn assay. However, diagnostic strategies based on such models may not perform as well when used in practice. Two Heart studies have made efficient use of existing data from large cohort studies to further evaluate the accuracy of those diagnostic strategies.3 ,4

Pickering et al3 pooled data from five cohort studies to examine the diagnostic accuracy of hs-cTn measured on arrival and 3 hours later, using standard cardiac troponin testing …

View Full Text


  • Twitter Follow Richard Body at @richardbody

  • Contributors All authors have contributed to drafting this manuscript and meet the criteria for authorship.

  • Competing interests The authors were specialist members of the panel providing recommendations to NICE on the use of high-sensitivity cardiac troponin to rule out non-ST elevation myocardial infarction.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles